Federal Register / Vol. 82, No. 206 / Thursday, October 26, 2017 / Notices 49663 

1Handbook for Electronic Filing Procedures: 

https://www.usitc.gov/documents/handbook_on_

filing_procedures.pdf. 

2All contract personnel will sign appropriate 

nondisclosure agreements. 

3Electronic Document Information System 

(EDIS): https://edis.usitc.gov. 

noon the next day pursuant to § 210.4(f) 

of the Commission’s Rules of Practice 

and Procedure (19 CFR 210.4(f)). 

Submissions should refer to the docket 

number (‘‘Docket No. 3266’’) in a 

prominent place on the cover page and/ 

or the first page. (See Handbook for 

Electronic Filing Procedures, Electronic 

Filing Procedures 1). Persons with 

questions regarding filing should 

contact the Secretary (202–205–2000). 

Any person desiring to submit a 

document to the Commission in 

confidence must request confidential 

treatment. All such requests should be 

directed to the Secretary to the 

Commission and must include a full 

statement of the reasons why the 

Commission should grant such 

treatment. See 19 CFR 201.6. Documents 

for which confidential treatment by the 

Commission is properly sought will be 

treated accordingly. All such requests 

should be directed to the Secretary to 

the Commission and must include a full 

statement of the reasons why the 

Commission should grant such 

treatment. See 19 CFR 201.6. Documents 

for which confidential treatment by the 

Commission is properly sought will be 

treated accordingly. All information, 

including confidential business 

information and documents for which 

confidential treatment is properly 

sought, submitted to the Commission for 

purposes of this Investigation may be 

disclosed to and used: (i) By the 

Commission, its employees and Offices, 

and contract personnel (a) for 

developing or maintaining the records 

of this or a related proceeding, or (b) in 

internal investigations, audits, reviews, 

and evaluations relating to the 

programs, personnel, and operations of 

the Commission including under 5 

U.S.C. Appendix 3; or (ii) by U.S. 

government employees and contract 

personnel,2 solely for cybersecurity 

purposes. All nonconfidential written 

submissions will be available for public 

inspection at the Office of the Secretary 

and on EDIS.3

This action is taken under the 

authority of section 337 of the Tariff Act 

of 1930, as amended (19 U.S.C. 1337), 

and of §§ 201.10 and 210.8(c) of the 

Commission’s Rules of Practice and 

Procedure (19 CFR 201.10, 210.8(c)). 

By order of the Commission. 

Issued: October 20, 2017. 

Lisa R. Barton, 

Secretary to the Commission. 

[FR Doc. 2017–23233 Filed 10–25–17; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Galephar Pharmaceutical 

Research, Inc. 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before November 27, 2017. Such 

persons may also file a written request 

for a hearing on the application on or 

before November 27, 2017. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for hearing must be 

sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/LJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DRW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on August 

2, 2017, Galephar Pharmaceutical 

Research, Inc., #100 Carr 198, Industrial 

Park, Juncos, Puerto Rico 00777–3873 

applied to be registered as an importer 

of hydromorphone (9150), a basic class 

of controlled substance in schedule II. 

The company plans to import the 

listed controlled substance in finished 

dosage form for clinical trials, research 

and analytical purposes. 

The import of this class of controlled 

substance will be granted only for 

analytical testing, research, and clinical 

trials. This authorization does not 

extend to the import of a finished FDA 

approved or non-approved dosage form 

for commercial sale. 

Dated: October 18, 2017. 

Demetra Ashley, 

Acting Assistant Administrator. 

[FR Doc. 2017–23328 Filed 10–25–17; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. 17–28] 

Yoon H. Choi, M.D.; Decision and 

Order 

On April 4, 2017, the Assistant 

Administrator, Division of Diversion 

Control, issued an Order to Show Cause 

to Yoon H. Choi, M.D. (Respondent), of 

Brockton, Massachusetts. The Show 

Cause Order proposed the revocation of 

Respondent’s DEA Certificate of 

Registration as a practitioner, on the 

ground that he does not have authority 

to dispense controlled substances in 

Massachusetts, the State in which he is 

registered with the Agency. Show Cause 

Order, at 1. 

As to the Agency’s jurisdiction, the 

Show Cause Order alleged that 

Respondent holds DEA Certificate of 

Registration No. BC6966381, which 

authorizes him to dispense controlled 

substances in schedules II through V as 

a practitioner, at the registered address 

of Steward Medical Group, One Pearl 

Street, Suite 2200, Brockton, 

Massachusetts. Id. The Show Cause 

Order alleged that this registration does 

not expire until August 31, 2018. Id. 

As to the substantive ground for the 

proceeding, the Show Cause Order 

alleged that ‘‘[o]n January 5, 2017, the 

Commonwealth of Massachusetts Board 

of Registration in Medicine indefinitely 

suspended [his] medical license’’ and 

that ‘‘[t]his order remains in effect.’’ Id. 

The Order thus alleged that Respondent 

is ‘‘without authority to handle 

controlled substances in . . . 

Massachusetts, the [S]tate in which [he 

is] registered,’’ that he is ‘‘required to 


ethrower on DSK3G9T082PROD with NOTICES